Below is a transcript of the testimonial by Dr. John Hawse from the Mayo Clinic in Rochester, MN, about the experience publishing his research paper, “ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer” with Oncotarget in 2017.
Dr. John Hawse
We had a fantastic experience.
This was actually our first manuscript that we had submitted from my laboratory to Oncotarget, but I would say that we had a fair review.
It went to four different reviewers, our particular manuscript did. All of the comments I thought were legitimate and were fair. We were able to address them successfully and have our manuscript accepted.
And following that, working with the team at Oncotarget to get the paper through the publication process has been quite rapid and easy.
YOU MAY ALSO LIKE: More Oncotarget Videos on LabTube
Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.
For media inquiries, please contact firstname.lastname@example.org.